The value of the infertility treatment industry in Poland will reach almost 98 million euros ($109 million) in 2016, according to Poland-based market intelligence company PMR.
The latest PMR report, Infertility treatment market in Poland 2015, found that, despite the introduction of the government’s in vitro reimbursement program, the majority of the industry’s revenues will come directly from patients. The level of public funds allocated in 2015-2016 will be lower than in 2014, but many couples who initiated treatment within the range of reimbursed services, will continue it at their own expense, meaning that the proportion of treatment paid for privately will increase in 2015-2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze